These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 31887777)

  • 1. Cost-Effectiveness and Budget Impact of Emicizumab Prophylaxis in Haemophilia A Patients with Inhibitors.
    Cortesi PA; Castaman G; Trifirò G; Creazzola SS; Improta G; Mazzaglia G; Molinari AC; Mantovani LG
    Thromb Haemost; 2020 Feb; 120(2):216-228. PubMed ID: 31887777
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Model of Short- and Long-Term Outcomes of Emicizumab Prophylaxis Treatment for Persons with Hemophilia A.
    Zhou ZY; Raimundo K; Patel AM; Han S; Ji Y; Fang H; Zhong J; Betts KA; Mahajerin A
    J Manag Care Spec Pharm; 2020 Sep; 26(9):1109-1120. PubMed ID: 32452276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic impact model of delayed inhibitor development in patients with hemophilia a receiving emicizumab for the prevention of bleeding events.
    Patel AM; Corman SL; Chaplin S; Raimundo K; Sidonio RF
    J Med Econ; 2019 Dec; 22(12):1328-1337. PubMed ID: 31530050
    [No Abstract]   [Full Text] [Related]  

  • 4. Evaluating the benefits of emicizumab prophylaxis for haemophilia A with inhibitors: A cost-effectiveness and budget impact analysis in Thailand's upper-middle income setting.
    Kengkla K; Wilairat P; Natesirinilkul R; Sosothikul D; Phisalprapa P; Saokaew S
    Haemophilia; 2024 Oct; ():. PubMed ID: 39368064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-utility analysis of emicizumab prophylaxis in haemophilia A patients with factor VIII inhibitors in Korea.
    Lee H; Cho H; Han JW; Kim AY; Park S; Lee M; Cho S; Baik D; Kang HY
    Haemophilia; 2021 Jan; 27(1):e12-e21. PubMed ID: 32894895
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison between on-demand usage of rFVIIa vs prophylaxis use of emicizumab in high titer inhibitory hemophilia A patients in Iran: A cost-utility analysis.
    Saiyarsarai P; Robabpour Derakhshan A; Khedmati J; Eshghi P; Seyedifar M
    Medicine (Baltimore); 2021 Oct; 100(40):e27303. PubMed ID: 34622828
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness analysis of emicizumab prophylaxis in patients with haemophilia A in India.
    Seth T; John MJ; Chakrabarti P; Shanmukhaiah C; Verma SP; Radhakrishnan N; Dolai TK
    Haemophilia; 2024 Mar; 30(2):426-436. PubMed ID: 38147060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The societal burden of haemophilia A. III - The potential impact of emicizumab on costs of haemophilia A in Australia.
    Brown LJ; La HA; Li J; Brunner M; Snoke M; Kerr AM
    Haemophilia; 2020 Aug; 26 Suppl 5():21-29. PubMed ID: 32935399
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of emicizumab vs bypassing agents in the prevention of bleeding episodes in haemophilia A patients with anti-FVIII inhibitors in France.
    Polack B; Trossaërt M; Cousin M; Baffert S; Pruvot A; Godard C
    Haemophilia; 2021 Jan; 27(1):e1-e11. PubMed ID: 33210412
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors.
    Young G; Liesner R; Chang T; Sidonio R; Oldenburg J; Jiménez-Yuste V; Mahlangu J; Kruse-Jarres R; Wang M; Uguen M; Doral MY; Wright LY; Schmitt C; Levy GG; Shima M; Mancuso ME
    Blood; 2019 Dec; 134(24):2127-2138. PubMed ID: 31697801
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness study of prophylaxis with emicizumab versus bypassing agents in patients with severe hemophilia A in Peru.
    Bitrán R; Peña C; Arpón P; Loayza N; Salas K; Del Villar C; Chumpitaz G; Salinas V
    Medwave; 2022 Mar; 22(2):e8703. PubMed ID: 35323824
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bispecific Antibody Emicizumab for Haemophilia A: A Breakthrough for Patients with Inhibitors.
    Mahlangu JN
    BioDrugs; 2018 Dec; 32(6):561-570. PubMed ID: 30430367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Budget Impact of Emicizumab for Routine Prophylaxis of Bleeding Episodes in Patients With Hemophilia A With Inhibitors.
    Watanabe AH; Lee SWH; Chai-Adisaksopha C; Lim MY; Chaiyakunapruk N
    Value Health Reg Issues; 2022 Mar; 28():7-13. PubMed ID: 34800834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of emicizumab prophylaxis on health-related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 Study.
    Oldenburg J; Mahlangu JN; Bujan W; Trask P; Callaghan MU; Young G; Asikanius E; Peyvandi F; Santagostino E; Kruse-Jarres R; Negrier C; Kessler C; Xu J; Windyga J; Shima M; von Mackensen S
    Haemophilia; 2019 Jan; 25(1):33-44. PubMed ID: 30427582
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study.
    Pipe SW; Shima M; Lehle M; Shapiro A; Chebon S; Fukutake K; Key NS; Portron A; Schmitt C; Podolak-Dawidziak M; Selak Bienz N; Hermans C; Campinha-Bacote A; Kiialainen A; Peerlinck K; Levy GG; Jiménez-Yuste V
    Lancet Haematol; 2019 Jun; 6(6):e295-e305. PubMed ID: 31003963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune tolerance induction in paediatric patients with haemophilia A and inhibitors receiving emicizumab prophylaxis.
    Batsuli G; Zimowski KL; Tickle K; Meeks SL; Sidonio RF
    Haemophilia; 2019 Sep; 25(5):789-796. PubMed ID: 31373431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-utility analysis of emicizumab for the treatment of severe hemophilia A patients in Canada.
    Yu JK; Wong WWL; Keepanasseril A; Iorio A; Edginton AN
    Haemophilia; 2023 Mar; 29(2):488-497. PubMed ID: 36528890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economic Evaluation of Immune Tolerance Induction in Children With Severe Hemophilia A and High-Responding Inhibitors: A Cost-Effectiveness Analysis of Prophylaxis With Emicizumab.
    Camelo RM; Barbosa MM; Araújo MS; Muniz RL; Guerra AA; Godman B; Rezende SM; Acurcio FA; Martin AP; Alvares-Teodoro J
    Value Health Reg Issues; 2023 Mar; 34():31-39. PubMed ID: 36463835
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emicizumab: A Review in Haemophilia A.
    Blair HA
    Drugs; 2019 Oct; 79(15):1697-1707. PubMed ID: 31542880
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world cost estimates of initiating emicizumab in US patients with haemophilia A.
    Samelson-Jones BJ; Guelcher C; Kuhn J; Butler R; Massey G; Guerrera MF; Raffini L
    Haemophilia; 2021 Jul; 27(4):591-598. PubMed ID: 34050689
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.